In vitro diagnostics in a recessionary economy ivd market forecasts, analysis and success strategies
Get more info on this report!In Vitro Diagnostics in a Recessionary Economy: IVD MarketForecasts, Analysis and Success StrategiesMay 1, 2009It is commonly asserted that in vitro diagnostics is a recession-proof industry. KaloramaInformations lead diagnostic analyst Shara Rosen tests that assumption and providesstrategic conclusions in Shara Rosens new report In Vitro Diagnostics in aRecessionary Economy.The economic problems that began slowing the U.S. economy keep spreading, withEurope and Japan following America into recession. The US is experiencing highunemployment rate and increased numbers of uninsured workers. But what impact isthe downturn having on in vitro diagnostic companies? What are the best areas of IVDand the best world markets? How should companies price and market their products?What are key companies in the market doing at this time? Among the topics covered inthis report: Current Market Estimates for Major Categories of IVD. Category Forecasts to 2014 Hospital Woes, Uninsured Patients, Payor Stress, and Other Trends industry observers need to know about. Current World Economic Conditions US, Europe and Emerging Markets Obama Administration Healthcare Reform Boom or Bust for IVD? Mergers and Acquisitions: Abbot - Ibis, QIAGEN - Corbett Life Science, J&J / Amic and several other competitive moves. Collaborations: Luminex and BD Tripath, Geisinger Health System and Celera, Sysmex and Epigenomics and other partnerships enacted as companies pool limited resources. Market Expansions: StatSensor Creatinine Meter (TM), Dako and BMS partnership and Others. New Testing Products Launched: BD Focal Point, Aureons Prostate Px+, New Abbott Marker for AKI and other new tests. Lab Service Commercialization Activities Lab IT Activity and the Involvement of High Tech Players such as Google and IBM. Success Strategies That are Working in 2009
Shara Rosen goes beyond just assessing the market and presents actions that IVDcompanies can take to assure growth in uncertain times. The report has a specialfocuses on developments in the United States since this is the largest single market forIVD products, but there is discussion of emerging world markets as well. The followingcompanies who have engaged in relevant competitive activities in recent months wereprofiled in this report: Abbott Diagnostics Beckman Coulter Inc. Becton, Dickinson and Company (BD) bioMerieux Inc. Celera Corporation Cellestis Ltd Cepheid Clarient Inc. (formerly ChromaVision) deCode Genetics Inc. Genomic Health Gen-Probe Inc. Immucor, Inc. Inverness Medical Innovations Luminex Corporation Monogram Biosciences, Inc. Nanogen Ortho Clinical Diagnostics (OCD) Qiagen N.V. Quidel Corporation Roche Diagnostics Seegene, Inc. Sequenom, Inc. Siemens Medical Solutions Diagnostics Sysmex Corporation Vermillion/Ciphergen Biosystems Inc.This Kalorama Information report is a work of primary research. Although secondarysources were used, the analysts years of experience, interviews with industry expertsand the latest findings of the 2009 Diagnostic Marketing Association Conference inChicago IL were part of this reports foundation.TABLE OF CONTENTSCHAPTER ONE: Executive Summary Scope and Methodology Market Trends World Demand for Diagnostics Keys to Success
CHAPTER TWO: Introduction Background Marketing in a recession - what the experts say about the 4Ps Obama’s new deal - boom and bust Musings on what form a reformed U.S. system might take Status quo and future - impressing investors in a bear marketCHAPTER THREE: Market Trends/Demand Analysis Hospital financing The role of new deal for the insured, uninsured and underinsured Payer response to economic stress Demand for esoteric tests World market for IVD tests and services o 2009 Market Estimates (N. America, EU West Europe, Japan, China, Latin America, India, EU East Europe, ROW) o 2014 Market Forecasts (N. America, EU West Europe, Japan, China, Latin America, India, EU East Europe, ROW) o Economic Conditions in United States of America o Economic Conditions in Europe o Economic Conditions in Japan o Economic Conditions in ChinaCHAPTER FOUR: Market Overview/Supply Analysis Market Analysis, revenue estimates 2007 - 2015 IVD Sectors Revenues o Clinical Chemistry, o Immunoassays - non isotopic Infectious Diseases o Other Immunos o Blood Bank Screening o Hematology o Microbiology (ID/AST) o Molecular Microbiology o Radioimmunoassays o Coagulation o Histology/Cytology o Nucleic Acid Assays o Blood Grouping/Typing o Blood Bank Molecular o Flow Cytometry o POC -OTC diabetes o POC -OTC other o POC -Professional/Hospital IVD Events
o New Tests and Technologies Abbott Diagnostics Adnavance Technologies Arbor Vita Corporation Arcxis Biotechnologies and Roche Assay Designs Aureon Laboratories Bayer Healthcare BD Diagnostics bioMérieux BRAHMS Caris Diagnostics CISBIO Bioassays Decision Biomarkers DexCom Diagnostic HYBRIDS Fujirebio Diagnostics GeneNews InVivoScribe Technologies Network Biosystems o Acquisitions, Mergers Abbott Diagnostics-Ibis Beckman Coulter-Nephromics Exiqon A/S-Oncotech GE Healthcare-Whatman Others o Collaborations o Market Expansion Activities o Lab Services o Lab Information Google IBM Intel Corporation General Data Company TechnologyCHAPTER FIVE: Company Profiles Abbott Diagnostics Beckman Coulter Inc. Becton, Dickinson and Company (BD) bioMerieux Inc. Celera Corporation Cellestis Ltd Cepheid Clarient Inc. (formerly ChromaVision) deCode Genetics Inc.
Genomic Health Gen-Probe Inc. Immucor, Inc. Inverness Medical Innovations Luminex Corporation Monogram Biosciences, Inc. Nanogen Ortho Clinical Diagnostics (OCD) Qiagen N.V. Quidel Corporation Roche Diagnostics Seegene, Inc. Sequenom, Inc. Siemens Medical Solutions Diagnostics Sysmex Corporation Vermillion/Ciphergen Biosystems Inc.CHAPTER SIX: Conclusion Pricing Strategy Marketing Strategy Supply and Demand TABLE OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY Figure 1-1: Growth Rates Compared: World RegionsCHAPTER TWO: INTRODUCTION Table 2-1: Selected IVD Venture InvestmentsCHAPTER THREE: MARKET TRENDS/DEMAND ANALYSIS Table 3-1: Number of People Worldwide Who Get Chronic Diseases Every Year Table 3-2: Percent Change in Industrial Productivity, by Country or Region, December 2007 to December 2008 Table 3-3: Worldwide In Vitro Diagnostic Reagent Sales by country, 2009-2014 Table 3-4: Europe Unemployment Rates and % change in GDPCHAPTER FOUR: Market Overview/Supply Analysis Table 4-1 Worldwide In Vitro Diagnostic Reagent Sales by Product Segment, 2009-2014 (Clinical Chemistry, Immunoassays, Blood Bank Screening, Hematology, Microbiology, Radioimmunoassays, Coagulation, Histology/Cytology, Nucleic Acid Assays, Blood Grouping/Typing, Blood Bank
Molecular, Flow Cytometry, POC OTC diabetes, POC, OTC Other, POC, Professional/Hospital)CHAPTER SIX: Conclusion Table 6-1: Pricing Structures That Create Value for the CustomerAvailable immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=2155316US: 800.298.5699UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004